Summary
Abbott Laboratories reported a net loss of $223.6 million, or -$0.14 per diluted share, for the first quarter of 2001, a significant decline from a net income of $693.0 million, or $0.44 per diluted share, in the same period of 2000. This downturn was primarily driven by a substantial charge of $1.015 billion for acquired in-process research and development related to the acquisition of BASF's pharmaceutical business. Despite the net loss, the company's net sales increased by 6.2% to $3.56 billion, largely boosted by the aforementioned acquisition. Excluding the significant one-time charge, adjusted operating results would paint a more positive picture, with operating cash flow expected to remain strong. Investors should note the substantial investment in growth through the Knoll acquisition, which is expected to yield long-term benefits, but has created short-term earnings pressure. The company also faces ongoing litigation, including antitrust suits and investigations related to the marketing practices of its joint venture, TAP Pharmaceutical Products Inc. While these matters are significant, management believes their ultimate disposition will not materially adversely affect the company's financial position. The balance sheet shows increased short-term borrowings to finance the Knoll acquisition, leading to a negative working capital position at the end of the quarter, offset by strong available credit lines. The dividend per common share increased to $0.21 from $0.19 in the prior year's comparable quarter, signaling continued confidence in future cash flows.
Key Highlights
- 1Net loss of $223.6 million for Q1 2001, compared to a net income of $693.0 million in Q1 2000, largely due to a $1.015 billion charge for acquired in-process R&D.
- 2Net sales increased 6.2% to $3.56 billion, driven by the acquisition of BASF's pharmaceutical business (Knoll).
- 3The acquisition of Knoll was completed for approximately $6.9 billion, significantly impacting the balance sheet with increased short-term borrowings.
- 4Operating cash flow was negative ($96.4 million) for Q1 2001, but excluding the acquired in-process R&D, it would have been positive ($919 million).
- 5The company reported a negative working capital of approximately $2.7 billion at March 31, 2001, due to acquisition financing.
- 6Diluted loss per share was $0.14 in Q1 2001, versus diluted earnings per share of $0.44 in Q1 2000.
- 7The company is involved in several ongoing legal proceedings, including antitrust suits and investigations into TAP Pharmaceutical Products Inc., though management expects no material adverse effect.